OneSource Specialty Pharma Ltd Q1 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/oabbbd12kmydt4z6jem04oz1.pdf

Key Takeaways


Capacity Expansion: The Core Growth Unlock

Neeraj Sharma: "Till now we have been really struggling to meet the demand because of one line was heavily overbooked. And the reason for us to add new line, not new line, but new lines is because, we have a very clear visibility on the demand."

Semaglutide & GLP-1: The Demand Engine

Neeraj Sharma: "Despite the temporary disruption in supplies which has been announced by Dr. Reddy's, our available capacities are full, thanks to really our customer base which spans across markets and across companies. And this has really helped us pull the demand while the DRL supplies resume."

Business Lines: Diversification Beyond GLP-1

Business LineStatusGrowth Drivers
Drug Device Combination▲ ScalingSemaglutide commercialization in Canada and India; Europe opens FY29–30, then US with FTF customers; order book described as "very clear."
Biologics▲ Pipeline buildingFormycon partnership added; RFP funnel 4x what it was a year ago, spanning innovators, biosimilars and animal health; commercial revenues from current customers start FY29 onwards; near-term revenues are development MSAs.
Soft Gelatin▲ CDMO pivotPreviously captive to Strides' IP-led products; now offering CDMO services with significant interest after European players faced challenges; new capacity expected fully taken over 12–15 months; greenfield initiated.
Injectables▬ Steady scarcity playFocused on products requiring dedicated manufacturing (penicillin, one of few FDA-approved plants globally) and products perpetually on FDA shortage list; customers value sustained supply over low prices; new pre-filled syringe and lyophilization capacity being added.

Margins: Upfronted Costs, Back-Ended Leverage


Biologics: The FY29 and Beyond Story

Neeraj Sharma: "Our pipeline, I think this is what, it's important for us to say, that the pipeline continues to be built with our RFP funnel today is almost 4x of what it was just over a year ago. And this spans across innovators, biosimilars, as well as animal health companies."

Regulatory & Operational Resilience

Neeraj Sharma: "Our injectable business is very, very focused on scarcity play... we either go for products which are very, which require dedicated manufacturing like penicillin. We have one of the few FDA-approved penicillin plants anywhere in the world with an absolutely excellent compliance track record. Thanks to which, we have a significant share of penicillin in the US and the products which are perpetually in FDA shortage list."

Guidance & Commitments

CommitmentSpecificsTimeline
Organic revenue target$400 millionFY28
EBITDA margin target40%FY28
Second cartridge line commercializationDoubles sterile production daysQ1 FY27
Third sterile line installationMakes OneSource one of very few global CDMOs at this scale with end-to-end capabilityWithin FY27
Fourth sterile line availabilityCovers demand from new markets opening FY28–29FY28
Soft gelatin capacity fillNew CDMO capacity completely takenNext 12–15 months
Injectable new capability (PFS, lyo)Available for full yearFY28
Biologics commercial revenuesFrom current customersFY29 onwards
Sequential revenue and EBITDA improvementQuarter-on-quarterThrough FY27

Key Metrics

MetricQ1 FY27
Revenue₹449 crore, +37% YoY
EBITDA₹123.3 crore, +39% YoY and +34% QoQ
EBITDA margin27.5% (per an analyst's math)
FY28 organic revenue guidance$400 million, reiterated
FY28 EBITDA margin guidance40%, reiterated
Generic pen market share (India)>40% of generic pens sold, as of June 26
New product launches9 during the quarter
New customer logos added6 during the quarter
Regulatory inspections passed12, including 2 surprise FDA audits across 2 sites
RFP funnel growth~4x versus just over a year ago
Capex program committed~80% of US$100 million capex committed
Sterile days per line per year~225 days per line; FY28 expected 675 days across 3 lines
Canada semaglutide approvals held3 out of 3 approvals in market with OneSource
India weight-loss pen market volume150,000–160,000 pens/month, up from <2,000 pens/month a year ago